Natural Product (NP) Details
General Information of the NP (ID: NP0944) | |||||
---|---|---|---|---|---|
Name |
Ferulic acid
|
||||
Synonyms |
ferulic acid; trans-Ferulic Acid; 1135-24-6; 537-98-4; 4-Hydroxy-3-methoxycinnamic acid; trans-4-Hydroxy-3-methoxycinnamic acid; 3-(4-Hydroxy-3-methoxyphenyl)acrylic acid; ferulate; (E)-Ferulic acid; Coniferic acid; 2-Propenoic acid, 3-(4-hydroxy-3-methoxyphenyl)-; 3-(4-Hydroxy-3-methoxyphenyl)-2-propenoic acid; Ferulic acid, trans-; Fumalic acid; (2E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoic acid; Cinnamic acid, 4-hydroxy-3-methoxy-; 3-methoxy-4-hydroxycinnamic acid; (E)-3-(4-Hydroxy-3-methoxyphenyl)-2-propenoic acid; MFCD00004400; UNII-AVM951ZWST; Cinnamic acid, 4-hydroxy-3-methoxy-, (E)-; (E)-4-Hydroxy-3-methoxycinnamic acid; (E)-4'-Hydroxy-3'-methoxycinnamic acid; (2E)-3-(4-Hydroxy-3-methoxyphenyl)-2-propenoic acid; 4-Hydroxy-3-methoxy cinnamic acid; Cinnamic acid, 4-hydroxy-3-methoxy-, trans-; 2-Propenoic acid, 3-(4-hydroxy-3-methoxyphenyl)-, (2E)-; AVM951ZWST; (E)-3-(4-hydroxy-3-methoxyphenyl)acrylic acid; (2E)-3-(4-Hydroxy-3-methoxyphenyl)acrylic acid; Ferulic acid dehydrogenation homopolymer; (E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoic acid; Fumalic acid (Ferulic acid); 4-Hydroxy-3-methoxycinnamate; CHEMBL32749; 2-Propenoic acid, 3-(4-hydroxy-3-methoxyphenyl)-, (E)-; 3-(4-Hydroxy-3-methoxyphenyl)-2-propenoic acid homopolymer; CHEBI:17620; NSC2821; 3-Methoxy-4-hydroxy-trans-cinnamate; 4-Hydroxy-3-Methoxycinnamic Acid, 99%; (E)-Ferulate; 3-(4-Hydroxy-3-methoxyphenyl)propenoic acid; 97274-61-8; CINNAMIC ACID,4-HYDROXY,3-METHOXY FERULIC ACID; caffeic acid 3-methyl ether; 3-methoxy-4-hydroxy-trans-cinnamic acid; SMR000112202; 3-(4-hydroxy-3-methoxyphenyl)prop-2-enoic acid; EINECS 208-679-7; ferulic acid (trans-4-hydroxy-3-methoxycinnamic acid); ferulasaure; trans-Ferulate; (E)-3-(4-Hydroxy-3-methoxyphenyl)-2-propenoate; CCRIS 3256; CCRIS 7127; CCRIS 7575; HSDB 7663; NSC 2821; Ferulic acid, E-; EINECS 214-490-0; NSC 51986; trans-4-Hydroxy-3-methoxycinnamicacid; Ferulic acid (M5); NSC 674320; PubChem8183; 3-(4-Hydroxy-3-methoxy-phenyl)-acrylic acid; Ferulic Acid ,(S); FERULIC-ACID; Ferulic Acid, Synthetic; Spectrum5_000554; bmse000459; bmse000587; bmse010211; trans-Ferulic acid, 99%; SCHEMBL15673; BSPBio_003168; MLS001066385; MLS001332483; MLS001332484; MLS002207079; MLS006011435; SPECTRUM1501017; trans-Ferulic acid, >=99%; (E)-3-(4-hydroxy-3-methoxy-phenyl)prop-2-enoic acid; ZINC58258; DTXSID70892035; HMS1921D05; HMS2269P04; (E)-4-Hydroxy-3-methoxycinnamate; trans-4-Hydroxy-3-methoxycinnamate; ALBB-013505; BCP21231; BCP21789; HY-N0060; NSC-2821; NSC51986; STR00961; (E)-4-hydroxy-3-methoxy-Cinnamate; (E)4-hydroxy-3-methoxycinnamic acid; BBL010345; BDBM50214744; CCG-38860; CF0041; NSC-51986; s2300; SBB000326; STK801551; AKOS000263735; AC-7965; ACN-035275; BCP9000163; DB07767; PS-3435; SDCCGMLS-0066667.P001; trans-3-methoxy-4-hydroxycinnamic acid; (E)-4-hydroxy-3-methoxy-Cinnamic acid; 3-(4-Hydroxy-3-methoxyphenyl)propenoate; 4-Hydroxy-3-methoxycinnamic acid, trans; NCGC00094889-01; NCGC00094889-02; NCGC00094889-03; NCGC00094889-04; AC-10321; BS-17543; SMR004703246; ST097625; AM20060784; CS-0007108; N1878; SW219616-1; trans-Ferulic Acid (purified by sublimation); C01494; J10038; J10187; W-2799; ferulic acid (4-hydroxy-3-methoxycinnamic acid); A829775; Q417362; SR-01000765539; (2E)-3-(4-Hydroxy-3-methoxyphenyl)-2-propenoate; J-002980; SR-01000765539-3; (E)-3-(3-methoxy-4-oxidanyl-phenyl)prop-2-enoic acid; 3-(4-HYDROXY-3-METHOXYPHENYL)PROP-2-ENOICACID; 055E203F-B305-4B7F-8CE7-F9C0C03AB609; 3986A1BE-A670-4B06-833B-E17253079FD8; Ferulic acid, European Pharmacopoeia (EP) Reference Standard; trans-Ferulic acid, certified reference material, TraceCERT(R); 2-Propenoic acid, 3-(4-hydroxy-3-methoxyphenyl)-, (E)- (9CI); Diethyl2-(acetamido)-2-(2-(bromomethyl)-5-nitrobenzyl)malonate; Ferulic acid, United States Pharmacopeia (USP) Reference Standard; trans-Ferulic acid, matrix substance for MALDI-MS, >=99.0% (HPLC); 4-Hydroxy-3-methoxycinnamic acid, mixture of isomers, analytical reference material; Ferulic Acid, Pharmaceutical Secondary Standard; Certified Reference Material; 831-85-6
Click to Show/Hide
|
||||
Species Origin | Ferula sinkiangensisK ... | Click to Show/Hide | |||
Ferula sinkiangensisK | |||||
Disease | Cervical cancer [ICD-11: 2C77] | Investigative | [1] | ||
Structure |
![]() |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C10H10O4
|
||||
PubChem CID | |||||
Canonical SMILES |
COC1=C(C=CC(=C1)C=CC(=O)O)O
|
||||
InChI |
1S/C10H10O4/c1-14-9-6-7(2-4-8(9)11)3-5-10(12)13/h2-6,11H,1H3,(H,12,13)/b5-3+
|
||||
InChIKey |
KSEBMYQBYZTDHS-HWKANZROSA-N
|
||||
CAS Number |
CAS 537-98-4
|
||||
ChEBI ID | |||||
Herb ID | |||||
SymMap ID | |||||
TCMSP ID | |||||
TTD Drug ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
Insulin | Acute diabete complication | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
Down-regulation | Activity | COX-2 | Molecule Info |
Pathway MAP
|
||
In-vivo Model | Overnight fasted rats (Adult male Sprague-Dawley rats) were injected intra-peritoneally with strepto zotocin (55 mg/kg) dissolved in citrate buffer (pH 4.5, 0.1 M) to induce diabetes. | |||||
Experimental
Result(s) |
Diabetic rats treated with insulin-FA combination demonstrated more pronounced beneficial effects as compared to either agent alone. | |||||
Atorvastatin | Cardiovascular disease | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [3] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Down-regulation | Expression | IL6 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | TNF | Molecule Info |
Pathway MAP
|
||
In-vivo Model | Male Swiss albino mice were given a diet containing high fat. | |||||
Experimental
Result(s) |
Simultaneous treatment with AS, F and their combination protected against HFD induced weight gain and oxidative stress. | |||||
2-methoxyestradiol | Pulmonary hypertension | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [4] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Down-regulation | Expression | HSPD1 | Molecule Info |
Pathway MAP
|
|
In-vitro Model | A-375 | CVCL_0132 | Amelanotic melanoma | Homo sapiens | ||
Experimental
Result(s) |
2-Methoxyestradiol and its combination with ferulic acid induces melanoma cell death via downregulation of Hsp60 and Hsp90. | |||||
ABT-888 | Malignant mesenchymal neoplasm | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [5] | |||||
Detail(s) |
Combination Info
![]() |
|||||
In-vitro Model | MDA-MB-231 | CVCL_0062 | Breast adenocarcinoma | Homo sapiens | ||
MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | |||
U2OS | CVCL_0042 | Osteosarcoma | Homo sapiens | |||
Experimental
Result(s) |
Ferulic acid in combination with PARP inhibitor sensitizes breast cancer cells as chemotherapeutic strategy. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Carbonic anhydrase (CA) | Molecule Info | [6] | |
Monoamine oxidase B (MAO-B) | Molecule Info | [7] | ||
BioCyc | Superpathway of tryptophan utilization | Click to Show/Hide | ||
2 | Tryptophan degradation via tryptamine | |||
3 | Dopamine degradation | |||
4 | Putrescine degradation III | |||
5 | Noradrenaline and adrenaline degradation | |||
KEGG Pathway | Glycine, serine and threonine metabolism | Click to Show/Hide | ||
2 | Arginine and proline metabolism | |||
3 | Histidine metabolism | |||
4 | Tyrosine metabolism | |||
5 | Phenylalanine metabolism | |||
6 | Tryptophan metabolism | |||
7 | Drug metabolism - cytochrome P450 | |||
8 | Metabolic pathways | |||
9 | Serotonergic synapse | |||
10 | Dopaminergic synapse | |||
11 | Cocaine addiction | |||
12 | Amphetamine addiction | |||
13 | Alcoholism | |||
Panther Pathway | Adrenaline and noradrenaline biosynthesis | Click to Show/Hide | ||
2 | 5-Hydroxytryptamine degredation | |||
3 | Dopamine receptor mediated signaling pathway | |||
Pathway Interaction Database | Alpha-synuclein signaling | Click to Show/Hide | ||
WikiPathways | Tryptophan metabolism | Click to Show/Hide | ||
2 | Dopamine metabolism | |||
3 | Phase 1 - Functionalization of compounds |





